{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:24:21Z","timestamp":1791350661409,"version":"4.3.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1016\/j.antiviral.2006.04.011","type":"journal-article","created":{"date-parts":[[2006,5,10]],"date-time":"2006-05-10T15:16:05Z","timestamp":1147274165000},"page":"282-292","source":"Crossref","is-referenced-by-count":71,"title":["Application of the cycloSal-prodrug approach for improving the biological potential of phosphorylated biomolecules"],"prefix":"10.1016","volume":"71","author":[{"given":"C.","family":"Meier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Balzarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2006.04.011_bib1","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1124\/mol.56.6.1354","article-title":"Intracellular metabolism of cycloSaligenyl 3\u2032-azido-2\u2032,3\u2032-dideoxythymidine monophosphate, a prodrug of 3\u2032-azido-2\u2032,3\u2032-dideoxythymidine (zidovudine)","volume":"56","author":"Balzarini","year":"1999","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.antiviral.2006.04.011_bib2","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1124\/mol.58.5.928","article-title":"CycloSaligenyl-2\u2032,3\u2032-didehydro-2\u2032,3\u2032-dideoxythymidine monophosphate (cycloSal-d4TMP): efficient intracellular delivery of d4TMP","volume":"58","author":"Balzarini","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.antiviral.2006.04.011_bib3","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/095632020101200505","article-title":"Antiviral activity of cyclosaligenyl prodrugs of acyclovir, carbovir and abacavir","volume":"12","author":"Balzarini","year":"2002","journal-title":"Antiviral Chem. Chemother."},{"key":"10.1016\/j.antiviral.2006.04.011_bib4","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2174\/1389557043403936","article-title":"Aryloxy phosphoramidate triesters as pro-tides","volume":"4","author":"Cahard","year":"2004","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.antiviral.2006.04.011_bib5","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/0006-2952(84)90649-X","article-title":"Biochemical aspects of the selective antiherpes activity of nucleoside analogues","volume":"33","author":"De Clercq","year":"1984","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2006.04.011_bib6","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/323464a0","article-title":"A novel selective broad-spectrum anti-DNA virus agent","volume":"323","author":"De Clercq","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2006.04.011_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrd703","article-title":"Strategies in the design of antiviral drugs","volume":"1","author":"De Clercq","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.antiviral.2006.04.011_bib8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2174\/1389557043403945","article-title":"Designing a pronucleotide stratagem: lessons from amino acid phosphoramidates of anticancer and antiviral pyrimidines","volume":"4","author":"Drontle","year":"2004","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.antiviral.2006.04.011_bib9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/095632020201300206","article-title":"Aryl-substituted and benzo-anellated cycloSal-derivatives of 2\u2032,3\u2032-dideoxy-2\u2032,3\u2032-didehydrothymidine monophosphate (d4TMP)\u2014correlation of structure, hydrolysis properties and anti-HIV activity","volume":"13","author":"Ducho","year":"2002","journal-title":"Antiviral Chem. Chemother."},{"key":"10.1016\/j.antiviral.2006.04.011_bib10","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1081\/NCN-120022667","article-title":"Are cholinesterases inhibited by cycloSal-nucleotides?","volume":"22","author":"Ducho","year":"2003","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.antiviral.2006.04.011_bib11","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1002\/ejoc.200300537","article-title":"3,5-t-butyl-6-fluoro-cycloSal-d4TMP\u2014a pronucleotide with a highly optimized masking group","author":"Ducho","year":"2003","journal-title":"Eur. J. Org. Chem."},{"key":"10.1016\/j.antiviral.2006.04.011_bib12","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1080\/15257779908041602","article-title":"Effects of cycloSal-d4TMP-derivatives in H9 cells with induced AZT resistance phenotype","volume":"18","author":"Gr\u00f6schel","year":"1999","journal-title":"Nucleosides Nucleotides"},{"key":"10.1016\/j.antiviral.2006.04.011_bib13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1203\/00006450-198002000-00117","article-title":"Familial psychmotor retardation with markedly low fluctuation serum proteins, FSH and GH levels, partial TBG deficiency, increased serum arylphosphatase A and increased CSF protein: a new syndrome?","volume":"14","author":"Jaeken","year":"1980","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.antiviral.2006.04.011_bib14","doi-asserted-by":"crossref","unstructured":"Jessen, H.J., Fendrich, W., Meier, C., 2006. Synthesis and Properties of fluorescent cycloSal-nucleotides based on the pyrimidine nucleoside m5K and its 2\u2032,3\u2032-dideoxy analog dm5K. Eur. J. Org. Chem. 924\u2013931.","DOI":"10.1002\/ejoc.200500532"},{"key":"10.1016\/j.antiviral.2006.04.011_bib15","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/15257779908041606","article-title":"Evidence for cyclophosphate formation during hydrolysis of 3-methyl-cycloSal-PCVMP","volume":"18","author":"Lomp","year":"1999","journal-title":"Nucleoside Nucleotides"},{"key":"10.1016\/j.antiviral.2006.04.011_bib16","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/07328319708006177","article-title":"CycloSaligenyl-5-fluoro-2\u2032-deoxyuridine monophosphate (cycloSal-FdUMP)\u2014a new pro-nucleotide approach","volume":"16","author":"Lorey","year":"1997","journal-title":"Nucleosides Nucleotides"},{"key":"10.1016\/j.antiviral.2006.04.011_bib17","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0006-2952(03)00290-9","article-title":"Cytosolic and mitochondrial deoxyribonucleotidases: activity with substrate analogs, inhibitors and implications for therapy","volume":"66","author":"Mazzon","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2006.04.011_bib18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0166-3542(99)00076-5","article-title":"Inhibitory effect of cycloSaligenyl-nucleoside monophosphates of acyclic nucleoside analogues on HSV-1 and EBV","volume":"45","author":"Meerbach","year":"2000","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2006.04.011_bib19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1055\/s-1998-1637","article-title":"Pro-nucleotides\u2014recent advances in the design of efficient tools for the delivery of biologically active nucleoside monophosphates","author":"Meier","year":"1998","journal-title":"Synlett"},{"key":"10.1016\/j.antiviral.2006.04.011_bib20","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1021\/jm970664s","article-title":"CycloSal-2\u2032,3\u2032-dideoxy-2\u2032,3\u2032-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system","volume":"41","author":"Meier","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2006.04.011_bib21","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/(SICI)1099-0690(199805)1998:5<837::AID-EJOC837>3.0.CO;2-7","article-title":"CycloSal-3\u2032-azido-2\u2032,3\u2032-dideoxythymidine monophosphate (cycloSal-AZTMP)\u2014an unexpected failure of nucleotide delivery from a proven pronucleotide system","author":"Meier","year":"1998","journal-title":"Eur. J. Org. Chem."},{"key":"10.1016\/j.antiviral.2006.04.011_bib22","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/095632029800900503","article-title":"Chemistry and anti-herpes simplex virus type 1 evaluation of cycloSal-nucleotides of acyclic nucleoside analogues","volume":"9","author":"Meier","year":"1998","journal-title":"Antiviral Chem. Chemother."},{"key":"10.1016\/j.antiviral.2006.04.011_bib23","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1021\/jm981096z","article-title":"CycloSal-pro-nucleotides (cycloSal-NMP) of 2\u2032,3\u2032-dideoxyadenosine (ddA) and 2\u2032,3\u2032-dideoxy-2\u2032,3\u2032-didehydroadenosine (d4A): synthesis and antiviral evaluation of a highly efficient nucleotide delivery system","volume":"42","author":"Meier","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2006.04.011_bib24","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1021\/jm981097r","article-title":"CycloSal-pro-nucleotides of 2\u2032-fluoro-ara- and 2\u2032-fluoro-ribo-2\u2032,3\u2032-dideoxyadenosine (F-ara- and F-ribo-ddA) as a strategy to bypass a metabolic blockade","volume":"42","author":"Meier","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2006.04.011_bib25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2174\/1389557023406205","article-title":"CycloSal-pronucleotides\u2014design of chemical trojan horses","volume":"2","author":"Meier","year":"2002","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.antiviral.2006.04.011_bib26","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1021\/jm0209275","article-title":"CycloSal-BVDUMP pronucleotides\u2014how to convert an anti-EBV-inactive nucleoside analogue into a bioactive compound","volume":"45","author":"Meier","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2006.04.011_bib27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2174\/1389557043403972","article-title":"\u201cLock-in\u201d-cycloSal-pronucleotides\u2014a new generation of chemical trojan horses","volume":"4","author":"Meier","year":"2004","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.antiviral.2006.04.011_bib28","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1021\/jm031032a","article-title":"Interaction of cycloSal-pronucleotides with cholinesterases from different origin\u2014a structure-activity relationship","volume":"47","author":"Meier","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2006.04.011_bib29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1081\/NCN-120027820","article-title":"Second generation of cycloSal-pronucleotides with esterase-cleavable sites\u2014the \u201clock-in\u201d-concept","volume":"23","author":"Meier","year":"2004","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.antiviral.2006.04.011_bib30","doi-asserted-by":"crossref","first-page":"8079","DOI":"10.1021\/jm050641a","article-title":"CycloSal-PMEA and cycloAmb-PMEA\u2014potentially new phosphonate prodrugs on the basis of the cycloSal-pronucleotide approach","volume":"48","author":"Meier","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2006.04.011_bib31","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2174\/156801205774322232","article-title":"CycloSal-pronucleotides of brivudin monophosphate\u2014highly active antiviral agents","volume":"4","author":"Meier","year":"2005","journal-title":"Curr. Med. Chem., Anti-Infective Agents"},{"key":"10.1016\/j.antiviral.2006.04.011_bib32","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/ejoc.200500490","article-title":"Development of second generation cycloSal-d4TMP pronucleotides bearing esterase-cleavable sites\u2014the trapping-concept","author":"Meier","year":"2006","journal-title":"Eur. J. Org. Chem."},{"key":"10.1016\/j.antiviral.2006.04.011_bib33","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/15257779908041605","article-title":"Phosphoramidite chemistry for the synthesis of cycloSal-pro-nucleotides","volume":"18","author":"Mugnier","year":"1999","journal-title":"Nucleosides Nucleotides"},{"key":"10.1016\/j.antiviral.2006.04.011_bib34","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/ejoc.200300681","article-title":"CycloSaligenyl-mannose-1-monophosphates as a new strategy in CDG-Ia therapy: hydrolysis, mechanistic insights and biological activity","author":"Muus","year":"2004","journal-title":"Eur. J. Org. Chem."},{"key":"10.1016\/j.antiviral.2006.04.011_bib35","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2174\/1389557043404007","article-title":"SATE pronucleotides approaches: an overview","volume":"4","author":"Peyrottes","year":"2004","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.antiviral.2006.04.011_bib36","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.antiviral.2005.06.001","article-title":"In vitro activity of cycloSal-nucleoside monophosphates and polyhydroxycarboxylates against orthopoxviruses","volume":"67","author":"Sauerbrei","year":"2005","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2006.04.011_bib37","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/1098-1128(200011)20:6<417::AID-MED1>3.0.CO;2-Z","article-title":"Pronucleotides: toward the in vivo delivery of antiviral and anticancer nucleotides","volume":"20","author":"Wagner","year":"2000","journal-title":"J. Med. Res. Rev."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354206001239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354206001239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T19:18:19Z","timestamp":1555615099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354206001239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":37,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["S0166354206001239"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2006.04.011","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}